Cocrystal Pharma (Cocrystal Pharma) COGS-to-Revenue : 0.00 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Cocrystal Pharma COGS-to-Revenue?

Cocrystal Pharma's Cost of Goods Sold for the three months ended in Mar. 2024 was $0.00 Mil. Its Revenue for the three months ended in Mar. 2024 was $0.00 Mil.

Cocrystal Pharma's COGS to Revenue for the three months ended in Mar. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Cocrystal Pharma's Gross Margin % for the three months ended in Mar. 2024 was N/A%.

Cocrystal Pharma COGS-to-Revenue Historical Data

The historical data trend for Cocrystal Pharma's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cocrystal Pharma COGS-to-Revenue Chart

Cocrystal Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

Cocrystal Pharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Cocrystal Pharma COGS-to-Revenue Calculation

Cocrystal Pharma's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Cocrystal Pharma's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Cocrystal Pharma (NAS:COCP) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Cocrystal Pharma's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Cocrystal Pharma COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Cocrystal Pharma's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Cocrystal Pharma (Cocrystal Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cocrystal Pharma Inc (NAS:COCP) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

8CC:Germany

Address

19805 North Creek Parkway, Bothell, WA, USA, 98011

Website

https://www.cocrystalpharma.com

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).

Executives

Fred Hassan	director	C/O CARET GROUP,, 1100 HOLLAND DR., BOCA RATON FL 33487
Frost Phillip Md Et Al	director, 10 percent owner	4400 BISCAYNE BLVD, MIAMI FL 33137-3227
Pfenniger Richard C Jr	director	4400 BISCAYNE BLVD., MIAMI FL 33137
Raymond F Schinazi	director, 10 percent owner	1860 MONTREAL ROAD, TUCKER GA 30084
Anthony J Japour	director	19805 N. CREEK PARKWAY, BOTHELL WA 98011
Todd R. Brady	director	19805 N. CREEK PARKWAY, BOTHELL WA 98011
James Joseph Martin	officer: Interim CFO	4400 BISCAYNE BLVD, SUITE # 670, MIAMI FL 33157
Curtis Dale	officer: INTERIM CFO	1860 MONTREAL ROAD, TUCKER GA 30084
Douglas L Mayers	officer: CHIEF MEDICAL OFFICER	C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02139
Walt Addison Linscott	officer: GENERAL COUNSEL AND SECRETARY	1860 MONTREAL ROAD, TUCKER GA 30084
Jeffrey A Meckler	director	740 BROADWAY, 9TH FLOOR, NEW YORK NY 10003
David S Block	director
Hsiao Jane Ph D	director	4400 BISCAYNE BLVD, MIAMI FL 33137
Steven D Rubin	director	OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Roger D. Kornberg	director	345 WALSH ROAD, ATHERTON CA 94027